These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 3008315)
1. The incidence of cytomegalo- and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leucocyte interferon: a controlled study. Weimar W; Kramer P; Bijnen AB; Jeekel J; Rothbarth PH; Masurel N Scand J Urol Nephrol Suppl; 1985; 92():37-9. PubMed ID: 3008315 [No Abstract] [Full Text] [Related]
2. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. Hirsch MS; Schooley RT; Cosimi AB; Russell PS; Delmonico FL; Tolkoff-Rubin NE; Herrin JT; Cantell K; Farrell ML; Rota TR; Rubin RH N Engl J Med; 1983 Jun; 308(25):1489-93. PubMed ID: 6304513 [TBL] [Abstract][Full Text] [Related]
3. Herpesvirus infections in renal allograft recipients. Spencer ES Scand J Urol Nephrol; 1975 Mar 6-7; (29 Suppl):133-4. PubMed ID: 181840 [TBL] [Abstract][Full Text] [Related]
4. Cytomegalo and herpes simplex virus infections in renal transplant recipients. Wertheim P; Slaterus KW; Geelen JL; van der Noordaa J; Wilmink JM Scand J Urol Nephrol Suppl; 1985; 92():5-8. PubMed ID: 3008317 [TBL] [Abstract][Full Text] [Related]
5. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Kovarik J; Mayer G; Pohanka E; Schwarz M; Traindl O; Graf H; Smolen J Transplantation; 1988 Feb; 45(2):402-5. PubMed ID: 2830688 [TBL] [Abstract][Full Text] [Related]
6. Use of interferon in cytomegalovirus infections in man. Hirsch MS Tex Rep Biol Med; 1981-1982; 41():566-70. PubMed ID: 6302938 [No Abstract] [Full Text] [Related]
7. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072 [No Abstract] [Full Text] [Related]
8. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125 [TBL] [Abstract][Full Text] [Related]
9. The effects of viral infections on renal transplants and their recipients. Warrell MJ; Chinn I; Morris PJ; Tobin JO Q J Med; 1980; 49(194):219-31. PubMed ID: 6254109 [TBL] [Abstract][Full Text] [Related]
11. Effect of human interferon-beta on life-threatening viral pneumonitis in kidney transplant recipients. Takahashi K; Teraoka S; Yagisawa T; Fuchinoue S; Honda H; Toma H; Agishi T; Ota K Transplant Proc; 1987 Oct; 19(5):4089-95. PubMed ID: 2823438 [No Abstract] [Full Text] [Related]
12. Cytomegalovirus and Epstein-Barr virus-acquired immunity after Sandoglobulin prophylaxis in the pediatric renal transplant population. Ham JM; Bunchman TE; Campbell DA; Kershaw DB; Punch JD; Sedman AB; Turcotte JG; Merion RM Transplant Proc; 1994 Feb; 26(1):20-1. PubMed ID: 8108942 [No Abstract] [Full Text] [Related]
13. The relationship of epidemiology and treatment factors to infection and allograft survival in renal transplantation. Betts RF Birth Defects Orig Artic Ser; 1984; 20(1):87-99. PubMed ID: 6329375 [No Abstract] [Full Text] [Related]
14. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection. Chen JH; Mao YY; He Q; Wu JY; Lv R Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078 [TBL] [Abstract][Full Text] [Related]
15. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871 [No Abstract] [Full Text] [Related]
16. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation. Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976 [No Abstract] [Full Text] [Related]
17. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Kramer P; ten Kate FW; Bijnen AB; Jeekel J; Weimar W Lancet; 1984 May; 1(8384):989-90. PubMed ID: 6143968 [TBL] [Abstract][Full Text] [Related]
18. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381 [TBL] [Abstract][Full Text] [Related]
19. HLA-DRw6 as a risk factor for active cytomegalovirus but not for herpes simplex virus infection after renal allograft transplantation. Roenhorst HW; Tegzess AM; Beelen JM; Middeldorp JM; The TH Br Med J (Clin Res Ed); 1985 Sep; 291(6496):619-22. PubMed ID: 2992676 [TBL] [Abstract][Full Text] [Related]
20. Cellular immunity in herpes simplex and cytomegalovirus infections in renal allograft recipients. Spencer E; Møller-Larsen A; Andersen HK; Haahr S Proc Eur Dial Transplant Assoc; 1979; 16():745-6. PubMed ID: 232919 [No Abstract] [Full Text] [Related] [Next] [New Search]